Algernon Pharmaceuticals (Algernon Pharmaceuticals) ROCE % : -166.38% (As of Nov. 2023)

View and export this data going back to 2016. Start your Free Trial

What is Algernon Pharmaceuticals ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Algernon Pharmaceuticals's annualized ROCE % for the quarter that ended in Nov. 2023 was -166.38%.

Algernon Pharmaceuticals ROCE % Historical Data

The historical data trend for Algernon Pharmaceuticals's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Algernon Pharmaceuticals ROCE % Chart

Algernon Pharmaceuticals Annual Data

Trend

Aug15

Aug16

Aug17

Aug18

Aug19

Aug20

Aug21

Aug22

Aug23

ROCE %

Get a 7-Day Free Trial

-60.16

-100.86

-77.59

-80.42

-142.74

Algernon Pharmaceuticals Quarterly Data
	Feb19	May19	Aug19	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23	Nov23
ROCE %	Get a 7-Day Free Trial															-146.03	-124.48	-123.27	-152.22	-166.38

Algernon Pharmaceuticals ROCE % Calculation

Algernon Pharmaceuticals's annualized ROCE % for the fiscal year that ended in Aug. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Aug. 2023 )		(A: Aug. 2022 )		(A: Aug. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Aug. 2023 )		(A: Aug. 2022 )		(A: Aug. 2023 )
	=	-3.889	/	( ( (6.303 - 1.948)	+	(3.112 - 2.018) )	/ 2 )
	=	-3.889	/	( (4.355	+	1.094)	/ 2 )
	=	-3.889	/	2.7245
	=	-142.74 %

Algernon Pharmaceuticals's ROCE % of for the quarter that ended in Nov. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Nov. 2023 )		(Q: Aug. 2023 )		(Q: Nov. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Nov. 2023 )		(Q: Aug. 2023 )		(Q: Nov. 2023 )
	=	-1.524	/	( ( (3.112 - 2.018)	+	(2.882 - 2.144) )	/ 2 )
	=	-1.524	/	( ( 1.094	+	0.738 )	/ 2 )
	=	-1.524	/	0.916
	=	-166.38 %

(1) Note: The EBIT data used here is four times the quarterly (Nov. 2023) EBIT data.

Algernon Pharmaceuticals (OTCPK:AGNPF) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Algernon Pharmaceuticals ROCE % Related Terms

Thank you for viewing the detailed overview of Algernon Pharmaceuticals's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Algernon Pharmaceuticals (Algernon Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Algernon Pharmaceuticals Inc (OTCPK:AGNPF) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

AGW0:Germany AGN:Canada

Address

601 West Broadway, Suite 400, Vancouver, BC, CAN, V5Z 4C2

Website

https://www.algernonpharmaceuticals.com

Algernon Pharmaceuticals Inc is a clinical-stage drug development company focused on the disease areas of stroke, idiopathic pulmonary fibrosis and chronic cough. The company's business model is capital efficient and strives to deliver maximum shareholder value. Algernon's approach to drug discovery is based on the concept of drug repurposing. It operates in two reportable segments: the development of repurposed therapeutic drugs in Canada, and the facilitation of the Company's drug candidates into off-label phase II clinical trials (humans) in Australia.